Interpreting Subgroup Analyses and Real World Evidence in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan and the panel explore how clinicians interpret subgroup analyses, pivotal trial data, and real world evidence when managing metastatic castration sensitive prostate cancer (mCSPC). Dr. Alan H. Bryce, Dr. Murilo De Almeida Luz, and Dr. Jayram discuss the role of subgroup analyses by age, comorbidity status, and race, noting that these analyses can offer useful insights but should be interpreted cautiously because they are often exploratory and not powered for definitive conclusions. The panel also reviews findings from the ARASENS trial and discusses how the observed overall survival benefit and safety profile inform treatment considerations, particularly in older or medically complex patients. In addition, the physicians examine the growing role of real world evidence in mCSPC, including treatment persistence, discontinuation patterns, and tolerability in routine practice. Together, the discussion highlights how clinicians integrate clinical trial data with real world observations to support evidence informed treatment decisions in metastatic castration sensitive prostate cancer.